06660.HK
AIM Vaccine Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 1.48
−6.65%Year over year
Reported trailing growth
- Revenue
- -21.0%
- EBITDA
- +44.3%
- EBIT
- +13.1%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- +16.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.0%
- EBITDA
- +14.4%
- EBIT
- +1.4%
- Net income
- —
- EPS
- —
- Free cash flow
- -23.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026